Designing an Acid Reducing Agent-resistant Amorphous Dispersion of Calquence

Cover Articles
June 6, 2022
by Cathy Yarborough, Science Writer

Calquence (crystalline acalabrutinib) is one of many poorly soluble, weak base oral oncology drugs whose absorption is reduced by high stomach pH. Proton pump inhibitors (PPI) and other acid reducing agents (ARAs) increase gastric pH.